Commonwealth Equity Services LLC Raises Stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Commonwealth Equity Services LLC lifted its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 23.3% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 6,537 shares of the biopharmaceutical company’s stock after purchasing an additional 1,234 shares during the period. Commonwealth Equity Services LLC’s holdings in Alnylam Pharmaceuticals were worth $1,538,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also recently modified their holdings of the company. Allworth Financial LP lifted its holdings in Alnylam Pharmaceuticals by 6.8% in the 4th quarter. Allworth Financial LP now owns 597 shares of the biopharmaceutical company’s stock worth $140,000 after purchasing an additional 38 shares in the last quarter. Nixon Peabody Trust Co. lifted its holdings in shares of Alnylam Pharmaceuticals by 1.9% in the fourth quarter. Nixon Peabody Trust Co. now owns 2,293 shares of the biopharmaceutical company’s stock worth $540,000 after buying an additional 43 shares in the last quarter. IFP Advisors Inc lifted its holdings in shares of Alnylam Pharmaceuticals by 24.2% in the fourth quarter. IFP Advisors Inc now owns 241 shares of the biopharmaceutical company’s stock worth $57,000 after buying an additional 47 shares in the last quarter. Nwam LLC boosted its position in shares of Alnylam Pharmaceuticals by 5.8% during the fourth quarter. Nwam LLC now owns 906 shares of the biopharmaceutical company’s stock worth $213,000 after acquiring an additional 50 shares during the last quarter. Finally, SYM FINANCIAL Corp grew its stake in Alnylam Pharmaceuticals by 6.2% during the third quarter. SYM FINANCIAL Corp now owns 947 shares of the biopharmaceutical company’s stock valued at $260,000 after acquiring an additional 55 shares in the last quarter. 92.97% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have commented on ALNY. Needham & Company LLC reissued a “buy” rating and set a $320.00 price objective on shares of Alnylam Pharmaceuticals in a report on Friday, March 21st. Chardan Capital restated a “buy” rating and set a $300.00 price target on shares of Alnylam Pharmaceuticals in a report on Friday, March 21st. HC Wainwright lifted their price objective on Alnylam Pharmaceuticals from $400.00 to $500.00 and gave the stock a “buy” rating in a research note on Monday, February 24th. JPMorgan Chase & Co. upgraded Alnylam Pharmaceuticals from a “neutral” rating to an “overweight” rating and increased their target price for the company from $280.00 to $328.00 in a research report on Monday, March 24th. Finally, StockNews.com cut shares of Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, March 21st. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and twenty have given a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $312.30.

Insiders Place Their Bets

In other Alnylam Pharmaceuticals news, CMO Pushkal Garg sold 1,548 shares of the stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $251.67, for a total transaction of $389,585.16. Following the sale, the chief marketing officer now owns 11,989 shares of the company’s stock, valued at approximately $3,017,271.63. This trade represents a 11.44 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Kevin Joseph Fitzgerald sold 663 shares of the business’s stock in a transaction on Friday, February 14th. The stock was sold at an average price of $255.21, for a total value of $169,204.23. Following the completion of the transaction, the executive vice president now directly owns 14,321 shares of the company’s stock, valued at approximately $3,654,862.41. The trade was a 4.42 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 71,234 shares of company stock worth $19,958,097 in the last ninety days. 1.50% of the stock is owned by company insiders.

Alnylam Pharmaceuticals Trading Down 0.9 %

NASDAQ ALNY opened at $268.46 on Friday. The stock has a market cap of $34.92 billion, a PE ratio of -123.71 and a beta of 0.39. Alnylam Pharmaceuticals, Inc. has a 12 month low of $141.98 and a 12 month high of $304.39. The company’s 50-day moving average price is $259.86 and its 200-day moving average price is $260.53. The company has a current ratio of 2.78, a quick ratio of 2.71 and a debt-to-equity ratio of 15.27.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.03). Equities research analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.